查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096451

血管閉合裝置：市場洞察、競爭格局及市場預測 - 2034 年

Vascular Closure Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

血管閉合裝置市場概述

概述：

  • 2025年全球血管閉合裝置市值為16.4億美元，預計2034年將達27億美元。
  • 在2026年至2034年的預測期內，市場預計將以 5.70%的CAGR成長，這得益於心血管疾病患病率的上升、微創導管療法的日益普及、大口徑結構性心臟介入治療的擴展以及封堵裝置的持續技術進步。
  • 就閉合機制而言，到2025年，使用縫合線的細分市場將佔 38%的市場佔有率，推動血管閉合裝置市場的發展。
  • 依入路部位分類，到2025年，大腿部位佔 85%的市場佔有率，引領血管閉合裝置市場。
  • 就鞘套尺寸而言，到2025年，小直徑鞘管佔 72%的市場佔有率，引領血管閉合裝置市場。
  • 依最終用戶分類，醫院和診所領域引領血管閉合裝置市場，到2025年佔市場佔有率的68%。
  • 到2025年，北美佔血管閉合裝置市場的45%，佔據最大佔有率，而亞太地區預計將在2034年之前保持最快的成長速度。

血管閉合裝置是醫療設備，用於閉合導管介入手術（例如心臟導管插入術、冠狀動脈成形術或結構性心臟介入術）過程中發生的動脈或靜脈穿刺點。這些手術通常需要在皮膚上穿刺，並透過一個較小的穿刺點（例如鼠蹊部的股動脈或手腕的橈動脈）插入導管。手術結束時，需要閉合穿刺點以達到止血的目的，作為手動壓迫止血的替代或補充。為了善加了解這個市場，最有效的方法是認知到製造商根據「閉合機制」和「動脈穿刺點大小」產品系列進行分類。從閉合機制來看，縫合裝置使用外科縫線主動將血管壁拉近；膠原蛋白蛋白塞裝置使用可生物吸收的膠原蛋白錨釘和塞子密封穿刺點；密封劑裝置在血管外注入聚乙二醇或凝膠狀密封劑；夾式裝置使用小型金屬夾閉合動脈切口。專用的大口徑封堵器採用生物可吸收貼片、塞子或膜，專為最大的穿刺口而設計。以鞘套尺寸分類，市場可分為兩類：一類是用於診斷和冠狀動脈手術的5-10 法式小口徑封堵器，另一類是用於經導管主動脈瓣置換術、血管內動脈瘤修復術和其他結構性心臟介入手術的12-25 法式大口徑封堵器。後者是成長最快且戰略意義最為重大的細分市場。目前市場的特點是：大口徑結構性心臟疾病治療的擴展、向全生物可吸收封堵器的轉變，以及能夠實現當日出院的封堵器的日益普及。

血管閉合裝置市場的主要市場促進因素

  • 心血管疾病的發生率上升。根據DelveInsight估計，2023年，七大主要市場出現約2,600萬例動脈粥狀硬化性心血管疾病病例，預計2034年這數字將持續成長。
  • 糖尿病患者人數不斷增加。根據DelveInsight估計，到2024年，全球約有5.9億20至79歲的成年人患有糖尿病，預計到2050年，這一數字將達到8.54億。這迅速增加心血管疾病的風險。
  • 微創導管治療（如血管造影術、血管成形術和支架置入術）的使用不斷擴大，這些治療需要進入動脈並閉合動脈。
  • 大直徑結構性心臟治療，如經導管主動脈瓣置換術和血管內動脈瘤修復術，迅速發展，需要專門的大直徑閉合裝置。
  • 門診手術和治療能夠實現當日出院，這已成為日益成長的趨勢。血管閉塞裝置透過縮短止血時間和促進早期下床活動，為這一趨勢的實現提供了助力。
  • 技術不斷進步，包括生物可吸收材料、大直徑閉合系統以及下一代縫合線和密封劑裝置。
  • 各大製造商正積極開發新產品並獲得監管部門的批准，擴大閉迴路解決方案的範圍。

推動血管閉塞裝置市場成長的因素

市場促進因素

心血管疾病盛行率不斷上升

血管閉合器械市場的主要驅動力是全球心血管疾病及其相關危險因素的日益普遍，這推動了支撐整個血管閉合器械市場的經導管介入手術數量的成長。全球人口老化以及高血壓、肥胖和糖尿病等生活方式相關的危險因素，導致心血管疾病患者數量不斷增加。根據DelveInsight估計，2023年，七大主要市場的動脈粥狀硬化性心血管疾病病例將達到約2,600萬例，預計2034年這數字將持續成長。冠狀動脈疾病、結構性心臟疾病和周邊血管疾病的治療擴大採用經皮導管介入診斷和治療，每種方法都需要進入動脈或靜脈，然後將其閉合。因此，心血管疾病負擔的加重直接轉化為對血管閉合器械的需求。診斷性血管造影術、冠狀動脈成形術、電生理消融術以及結構性心臟疾病手術都會產生需要止血的穿刺部位，但血管閉合裝置能夠顯著減少出血和血管併發症，其效果遠超手動壓迫止血，還能縮短止血時間，並加快患者下床活動和出院。隨著心血管疾病負擔的加重以及接受介入治療而非手術治療的患者比例的上升，對血管閉合裝置的需求也隨之穩步成長，而心血管疾病負擔的加重是推動市場持續成長的最主要因素。

糖尿病和心血管風險患者人數的增加

全球糖尿病患者數量龐大且成長迅速，是血管閉合器械市場的重要驅動力。這是因為糖尿病會顯著增加心血管風險，進而增加對導管介入手術（包括使用閉合器械）的需求。根據DelveInsight估計，2024年全球約有5.9億20至79歲的成年人患有糖尿病，預計到2050年這一數字將達到8.54億。在美國，2024年約有3,860萬人患有糖尿病，預計到2050年這數字將增加至4,350萬人。與一般人群相比，糖尿病患者患冠狀動脈疾病、周邊動脈疾病和其他血管併發症的風險顯著更高，因此，他們接受血管造影術、血管成形術和其他導管介入診斷和治療手術的頻率也高於普通人群，而所有這些手術都需要進入血管並進行血管閉合。此患者族群出血和血管併發症的高風險進一步凸顯了可靠血管閉合術的臨床價值。這是因為糖尿病患者或接受抗凝血治療的患者尤其能從血管閉合裝置提供的快速可靠的止血中獲益。糖尿病的盛行率在全球持續上升，且呈現惡化趨勢，在新興市場尤其明顯，而這些市場正是介入性心臟病學系統蓬勃發展的地區。因此，糖尿病患者數量的不斷成長為市場創造了巨大、結構性且加速成長的需求來源，進一步加重了潛在心血管疾病的負擔。

市場限制因素

儘管需求不斷成長且使用者群體廣泛，但血管閉合器械市場仍面臨許多限制因素，阻礙了其普及應用。最重要的是，閉合器械本身存在併發症風險。雖然這些器械能夠縮短止血時間，使患者儘早下床活動，但它們也有出血、血腫、血管損傷、感染、假性動脈瘤和動脈閉塞等風險。此外，如果器械發生故障，可能需要手動壓迫、手術修復或其他干預措施。這些風險可能對患者造成嚴重傷害，並增加醫療成本，因此臨床醫生對此持謹慎態度。一些臨床醫生仍然傾向於對特定患者採用手動壓迫，這種情況限制了現有產品的普及，同時也凸顯了臨床對更安全材料和設計的需求。第二個限制因素是美國食品藥物管理局（FDA）和歐盟醫療設備法規等機構制定的嚴格監管標準。這些植入式和關鍵介入器材的核准流程漫長而昂貴，需要進行廣泛的臨床試驗以證明其安全性和有效性，並需持續進行上市後監測。這提高了新產品和小規模創新者的進入門檻，可能延遲市場進入或阻礙創新。第三個限制因素是來自手動壓迫和橈動脈入路的競爭。橈動脈入路手術出血風險較低，在冠狀動脈介入治療中越來越受歡迎，通常使用簡單的壓迫帶而非閉塞裝置進行止血，減緩了閉塞裝置在冠狀動脈領域的應用。其他限制因素包括閉塞裝置相對於手動壓迫的成本、來自競爭激烈的市場和聯合採購的價格壓力，以及由於進口零件和成品關稅導致的成本和供應波動。這些臨床、監管和經濟因素共同構成了結構性成長支撐，但也導致不同領域和地區的發展進程存在差異。資料來源：同行評審文獻、監管機構和公司資訊披露。

區域性說明

北美洲

北美在市場規模、創新和監管先鋒方面均主導，到2025年佔45%的市場佔有率。該地區心血管疾病和糖尿病發病率高，同時擁有先進的導管介入基礎設施、有利的保險償付機制、高額的醫療費用支出以及向門診手術的強勁成長動力。根據DelveInsight估計，2024年美國約有3,860萬名糖尿病患者，預計2050年這數字將增加至4,350萬人。美國是新型血管閉塞裝置（包括新一代靜脈和小口徑動脈系統）核准的基準市場。短期趨勢受以下因素影響：大口徑結構性心臟疾病治療的擴展、當日出院的普及、生物可吸收血管閉塞裝置的廣泛應用以及關稅導致的供應鏈重組。

歐洲

歐洲是一個規模龐大、創新驅動的市場，其發展動力源於心血管疾病負擔的日益加重、人口老化導致介入治療需求增加，以及微創技術（如血管成形術、經導管主動脈瓣置換術和血管內動脈瘤修復術）的積極應用。該地區通常是創新大口徑和生物可吸收系統的早期採用市場，受益於完善的醫療基礎設施、對導管介入治療投入的增加，以及醫生越來越傾向於使用閉合裝置而非手動壓迫。例如，完全生物可吸收、無需縫合的大口徑閉合裝置獲得了CE認證，並擴大了適應症範圍。許多歐洲國家的支持性保險償付計畫促進了產品的推廣應用，而歐盟醫療設備法規則提高了新核准所需的證據標準。

亞太地區

亞太地區是成長最快的地區，這主要得益於龐大且不斷成長的患者群體、糖尿病和心血管疾病患病率的上升以及微創手術的日益普及。中國、印度和日本基礎設施的快速發展為導管介入治療的成長提供了支持，而全球和區域領先企業的加大投資、完善的醫保償付體係以及政府舉措也加速了該成長。中國的成長佔有率最大，日本受益於人口老化加劇以及生物可吸收材料的早期應用，而印度則因其對價格的敏感性，蘊藏著巨大的長期發展機會。國際製造商和具有成本競爭力的區域製造商並存，擴大了醫療服務的覆蓋範圍，所有細分市場的成長率均超過全球平均水準。

世界其他地區

「世界其他地區」包括中東、非洲和南美洲。這些地區在醫療保健服務取得方面存在顯著差異。在波灣合作理事會（GCC）成員國和南美大型市場（尤其是巴西），人們投資開發導管介入和結構性心臟疾病治療系統，採用現代介入封堵術的病例也在增加，使其成為蓬勃發展的市場。另一方面，在非洲大部分地區，由於缺乏導管介入基礎設施、訓練有素的介入醫療專業人員以及必要的資金，大多數心血管疾病得不到治療。成本和償付方面的限制也限制了封堵裝置在開發中國家。預計該地區的成長將受到以下因素的推動：對心臟導管介入系統的投資、心血管疾病負擔的加重、政府的醫療保健政策以及來自區域和亞洲製造商的低成本器械的湧現。

  • 市場集中：市場經歷適度的整合，越來越多的公司著重大口徑、生物可吸收和靜脈阻塞技術，此外還有幾家大型醫療技術公司透過其成熟的阻塞設備業務佔據了大部分銷售額。
  • 主要參與者包括：Abbott憑藉其市場領先的Perclose縫合線產品線引領行業；Terumo Corporation憑藉其Angio-Seal膠原蛋白塞佔據了穩固的地位；Teleflex憑藉MANTA產品線在大口徑血管內視鏡領域展開競爭；以及Cardinal Health通過Cordis提供MYNX密封劑。Haemonetics也透過其Vascade產品組合以及對Vivasure的收購，拓展其靜脈輸液和大口徑血管內視鏡產品線。
  • 地理擴張：大型企業依靠與導管檢查室的合作關係，建立全球銷售和臨床教育機構。同時，Meril和Zylox-Tonbridge這樣的區域性製造商則利用成本優勢，迎合價格敏感型市場和新興市場的需求。
  • 產品系列優勢：外科醫師會根據手術流程選擇器械，而競爭優勢在於產品種類齊全的縫合機制和鞘套尺寸。產品組合涵蓋了從小直徑縫線、膠原蛋白和密封劑器械到專用大直徑系統等各種產品，這是決定性的競爭優勢。
  • 產品線優勢：研發重點在於用於治療結構性心臟疾病的專用大口徑閉塞裝置、完全生物可吸收和無縫線系統、下一代縫合式裝置和密封劑裝置，以及用於電生理和左心耳手術的靜脈閉塞裝置。
  • 策略聯盟：這些聯盟的範圍涵蓋了封閉式醫療器材研發公司與結構性心臟疾病計畫之間的合作，以及臨床試驗的夥伴關係。例如，Haemonetics 與 VivaSure、Teleflex 與 InSeal Medical 以及 Abbott 與 Essential Medical 之間的聯盟。
  • 併購活動：收購是該行業的重要趨勢，包括 Haemonetics 收購 Cardiva Medical 和 VivaSure Medical 以加強其大口徑和靜脈閉塞技術，Haemonetics 收購 Opsens，以及 Teleflex 同意收購 Biotronic 的血管介入業務以補充 MANTA。
  • 創新重點：創新正轉向大直徑和完全生物可吸收的閉合裝置、無縫線和快速吸收的密封劑技術、靜脈和結構性心臟疾病的閉合，以及將人工智慧（AI）整合到入路部位規劃和部署指導中。
  • 監管環境：在美國獲得上市前批准（PMA）和 510（k）許可，以及在歐盟獲得醫療設備法規（MDR）認證，代表著決定性的競爭優勢，而大口徑和靜脈阻塞裝置的批准順序是行業領導者之間競爭的關鍵軸心。

血管閉塞裝置市場近期發展趨勢

2026年1月，Haemonetics公司以1.16億美元的預付款收購了VivaSure Medical公司，透過其完全可生物吸收、無需縫合的PerQseal平台，將其業務拓展至大口徑結構性心臟疾病和血管內閉合領域。戰略意義：此次收購使這家快速發展的閉合器械專家在業內領先的完全可生物吸收大口徑平台和成長最快的市場細分領域站穩了腳跟。這將重塑主要廠商在大口徑閉合器械市場的佔有率，並加劇結構性心臟疾病領域的競爭。

常見問題：

問題1：血管閉合裝置市場的預期成長率是多少？

全球血管閉合裝置市場預計在2026年至2034年的預測期內將以 5.70%的CAGR成長。

Q2.血管閉合裝置市場的目前規模和預期規模是多少？

2025年全球血管閉合裝置市值為16.4億美元，預計2034年將達27億美元。

Q3.哪些地區推動血管閉合器械市場的發展？

到2025年，北美將以45%的市場佔有率引領血管閉合器械市場，主導心血管疾病和糖尿病的高發病率、人口老齡化、先進的導管介入基礎設施、有利的保險償付機制、高昂的醫療費用支出以及門診手術的強勁成長。根據DelveInsight估計，到2024年，美國將有約3,860萬名糖尿病患者。預計到2034年，亞太地區將實現最高的CAGR，這主要得益於其龐大且不斷成長的患者群體、糖尿病和心血管疾病患病率的上升，以及中國、印度和日本導管介入能力的不斷提升。

目錄

第1章 引言

  • 調查範圍
  • 市場區隔
  • 市場概覽

第2章 血管閉合裝置：執行摘要

  • 主要亮點和市場概覽

第3章 影響血管閉合裝置市場的關鍵因素

  • 市場促進因素
    • 心血管疾病和糖尿病盛行率增加
    • 微創手術的廣泛應用
    • 擴大大直徑結構性心臟疾病的治療範圍
    • 技術進步和生物可吸收材料
  • 市場限制因素
    • 與閉合裝置相關的併發症風險
    • 嚴格的監管標準
    • 與手動壓迫和橈動脈入路方法競爭。
  • 市場機會
    • 完全可生物吸收的大直徑閉塞裝置
    • 靜脈阻塞與新興市場

第4章 影響分析：人工智慧、地緣政治、貿易和經濟趨勢

第5章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第6章 波特五力分析

  • 供應商的議價能力
  • 消費者議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭公司之間的競爭

第7章 血管閉合裝置市場評估

  • 依閉合機制
    • 縫合介導裝置（主動式合攏器）
    • 膠原蛋白塞裝置
    • 密封劑和凝膠基裝置
    • 夾式裝置
    • 專用大直徑閉合裝置（補片、塞子、膜片）
    • 輔助加壓裝置和其他
  • 依入路部位
    • 大腿
    • 橈動脈
  • 鞘套尺寸
    • 小直徑（5~10F）
    • 大直徑（12~25F）
  • 依最終用戶
    • 醫院和診所
    • 門診手術中心
    • 其他
  • 依地區
    • 北美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第8章 血管閉合器械市場的競爭格局

  • 競爭分析
  • 企業市場占有率分析（加值服務）

第9章 血管閉合器械市場的新創企業資金籌措與投資趨勢

第10章 公司簡介與產品簡介

  • Abbott Laboratories
    • 公司簡介
    • 公司簡介
    • 財務概覽
    • 產品列表
    • 策略舉措/熵
  • Terumo Corporation
  • Teleflex Incorporated
  • Cardinal Health（Cordis）
  • Haemonetics Corporation
  • Medtronic plc
  • Merit Medical Systems Inc.
  • Becton, Dickinson and Company（BD）
  • Vivasure Medical Ltd.
  • Vasorum Ltd.

第11章 KOL的觀點

第12章 專案方法

第13章 關於 DelveInsight

第14章 免責聲明與聯絡方式

Product Code: DIMDCL0106

Vascular Closure Devices Market Summary

Overview:

  • The global vascular closure devices market was valued at USD 1.64 billion in 2025 and is projected to reach USD 2.70 billion by 2034.
  • The market is expected to expand at a CAGR of 5.70% during the forecast period 2026-2034, supported by the rising prevalence of cardiovascular disease, the growing adoption of minimally invasive catheter-based procedures, the expansion of large-bore structural heart interventions, and continuous technological advancement in closure devices.
  • By closure mechanism, the suture-mediated segment dominated the vascular closure devices market with a 38% share in 2025.
  • By access site, the femoral segment dominated the vascular closure devices market with an 85% share in 2025.
  • By sheath size, the small-bore segment dominated the vascular closure devices market with a 72% share in 2025.
  • By end-user, the hospitals and clinics segment dominated the vascular closure devices market with a 68% share in 2025.
  • North America accounted for the largest share of the vascular closure devices market at 45% in 2025, while Asia-Pacific is anticipated to register the fastest growth through 2034.

A vascular closure device is a medical device used to seal the puncture in an artery or vein created during a catheter-based procedure such as cardiac catheterization, coronary angioplasty, or a structural heart intervention. During these procedures, a catheter is inserted through a small percutaneous puncture, most commonly in the femoral artery of the groin or the radial artery of the wrist, and at the end of the procedure the access site must be closed to achieve hemostasis, replacing or supplementing manual compression. The market is best understood by the way manufacturers organize their portfolios, which is by the mechanism of closure and by the size of the arterial puncture. By mechanism, suture-mediated devices deploy a surgical suture to actively approximate the vessel wall, collagen-plug devices seal the puncture with a bioabsorbable collagen anchor and plug, sealant devices deploy an extravascular polyethylene glycol or gel sealant, clip-based devices close the arteriotomy with a small metal clip, and dedicated large-bore devices use bioresorbable patches, plugs, or membranes designed for the largest punctures. By sheath size, the market divides between small-bore closure for the 5 to 10 French access of diagnostic and coronary procedures and large-bore closure for the 12 to 25 French access of transcatheter aortic valve replacement, endovascular aneurysm repair, and other structural heart interventions, which is the fastest-growing and most strategically important segment. The contemporary market is defined by the expansion of large-bore structural heart procedures, the shift toward fully bioresorbable closure, and the growing use of closure to enable same-day discharge.

Vascular Closure Devices Market Key Growth Drivers

  • Rising prevalence of cardiovascular disease, with DelveInsight estimating that the seven major markets accounted for some 26 million cases of atherosclerotic cardiovascular disease in 2023, projected to rise further by 2034.
  • A large and growing diabetic population, with DelveInsight estimating that some 590 million adults aged 20 to 79 were living with diabetes worldwide in 2024, projected to reach 854 million by 2050, which sharply elevates cardiovascular risk.
  • Growing adoption of minimally invasive catheter-based procedures such as angiography, angioplasty, and stenting that require arterial access and closure.
  • The rapid expansion of large-bore structural heart procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair, which require dedicated large-bore closure.
  • The shift toward outpatient and same-day-discharge procedures, which vascular closure devices facilitate by shortening time to hemostasis and enabling earlier ambulation.
  • Continuous technological advancement, including bioabsorbable materials, large-bore closure systems, and next-generation suture-based and sealant devices.
  • Rising product development and regulatory approval activity among the leading manufacturers, broadening the range of closure solutions.

Key Companies in Vascular Closure Devices Market

The competitive field is led by a small group of large medical technology companies operating established closure franchises, challenged by specialists in large-bore and fully bioresorbable closure and by regional manufacturers. The leading participants in the vascular closure devices market include the following:

  • Abbott Laboratories
  • Terumo Corporation
  • Teleflex Incorporated
  • Cardinal Health (Cordis)
  • Haemonetics Corporation
  • Medtronic plc
  • Merit Medical Systems Inc.
  • Becton, Dickinson and Company (BD)
  • Vivasure Medical Ltd.
  • Vasorum Ltd.

Factors Contributing to the Growth of the Vascular Closure Devices Market

Market Drivers

Rising Prevalence of Cardiovascular Disease

The foundational driver of the vascular closure devices market is the rising global prevalence of cardiovascular disease and its associated risk factors, which generates the volume of catheter-based procedures on which the entire category depends. An aging global population and lifestyle-related risk factors including hypertension, obesity, and diabetes are increasing the number of patients with cardiovascular disease, and DelveInsight estimates that the seven major markets accounted for some 26 million cases of atherosclerotic cardiovascular disease in 2023, a figure projected to rise further by 2034. Because coronary artery disease, structural heart disease, and peripheral vascular disease are managed increasingly through percutaneous catheter-based diagnosis and intervention, each requiring arterial or venous access that must subsequently be closed, the growing cardiovascular disease burden translates directly into demand for closure devices. Every diagnostic angiogram, coronary angioplasty, electrophysiology ablation, and structural heart procedure creates an access site that must achieve hemostasis, and closure devices reduce the bleeding and vascular complications, shorten the time to hemostasis, and accelerate ambulation and discharge that manual compression cannot match. As the cardiovascular disease burden rises and as a larger share of patients is managed interventionally rather than surgically, the base of procedures generating closure demand expands steadily and predictably, making the cardiovascular disease burden the most durable driver of the market.

Growing Diabetic Population and Cardiovascular Risk

The large and rapidly growing global diabetic population is a powerful driver of the vascular closure devices market, because diabetes sharply elevates cardiovascular risk and the need for the catheter-based procedures that closure devices support. DelveInsight estimates that some 590 million adults aged 20 to 79 were living with diabetes worldwide in 2024, a figure expected to reach 854 million by 2050, and in the United States some 38.6 million people were living with diabetes in 2024, projected to rise to 43.5 million by 2050. Diabetic patients face a substantially higher risk of coronary artery disease, peripheral arterial disease, and other vascular complications, and they consequently undergo angiography, angioplasty, and other catheter-based diagnostic and interventional procedures at higher rates than the general population, each of which requires arterial access and closure. The elevated bleeding and vascular complication risk in this population further increases the clinical value of reliable closure, since diabetic and anticoagulated patients benefit particularly from the rapid and secure hemostasis that closure devices provide. Because the diabetes epidemic is a durable and worsening global trend that is especially pronounced in the same emerging markets where interventional cardiology capacity is expanding, the growing diabetic population adds a large, structural, and accelerating source of demand to the market and reinforces the cardiovascular disease burden that underpins it.

Market Restraints

Despite a growing and broadly based demand, the vascular closure devices market faces material constraints that temper the pace of adoption. The most significant is the risk of complications associated with closure devices themselves. While these devices reduce the time to hemostasis and support early ambulation, they carry risks including bleeding, hematoma, vessel injury, infection, pseudoaneurysm, and arterial occlusion, and device failure can necessitate manual compression, surgical repair, or further intervention. These risks can lead to serious patient harm, increased healthcare costs, and a cautious approach among clinicians, some of whom continue to prefer manual compression in selected patients, and they underscore the clinical demand for safer materials and designs even as they constrain adoption of existing ones. The second constraint is the stringent regulatory standard imposed by authorities such as the United States Food and Drug Administration and the European Union Medical Device Regulation. The approval process for these implantable and access-critical devices is long, costly, and requires extensive clinical trials to demonstrate safety and efficacy, together with continuous post-market surveillance, which raises the barrier to entry for new products and smaller innovators and can delay market entry and stifle innovation. The third constraint is competition from manual compression and from the shift toward radial access, since transradial procedures, which carry a lower bleeding risk and are increasingly preferred for coronary intervention, are frequently managed with a simple compression band rather than a closure device, moderating closure device penetration in the coronary segment. Additional constraints include the cost of closure devices relative to manual compression, pricing pressure from competitive markets and consolidated purchasing, and the volatility that tariffs on imported components and finished devices add to cost and supply. Together, these clinical, regulatory, and economic factors ensure that growth, while structurally supported, proceeds unevenly across segments and geographies. Source: peer-reviewed literature; regulatory authorities; company disclosures.

Vascular Closure Devices Market Segment Analysis

The global vascular closure devices market is segmented by closure mechanism (suture-mediated devices, collagen-plug devices, sealant and gel-based devices, clip-based devices, and dedicated large-bore closure devices), by access site (femoral and radial), by sheath size (small-bore and large-bore), by end-user (hospitals and clinics, ambulatory surgical centers, and others), and by geography (North America, Europe, Asia-Pacific, and the Rest of the World).

By Closure Mechanism

Dominant Subsegment: Suture-Mediated Devices.

The suture-mediated category is expected to dominate the market.

Dominant: Suture-Mediated ~ 38%

The suture-mediated segment accounted for a 38% share of the vascular closure devices market in 2025. Suture-mediated devices dominate the closure-mechanism structure because they provide a highly reliable and versatile solution for sealing arterial access sites across the widest range of sheath sizes, from routine coronary access through the large-bore access of structural heart procedures. These devices use a precise suture-mediated mechanism to actively approximate and close the vessel wall, which delivers strong, durable hemostasis and, unlike collagen-based devices, leaves no re-access restriction and permits immediate durable closure without the anchor and plug that a collagen device retains. Their defining advantage is applicability to large-bore closure, since suture-mediated devices such as the Abbott Perclose ProGlide and ProStyle can be deployed singly or in combination to close the large punctures of transcatheter aortic valve replacement and endovascular aneurysm repair, making them the foundation device and the current standard of care for large-bore access, and the Perclose franchise is the global market share leader. Collagen-plug devices, exemplified by the Terumo Angio-Seal, constitute a large and clinically entrenched segment valued for three decades of safety data and a thrombin-rich matrix that accelerates clot formation. Sealant and gel-based devices such as the Cordis MYNX seal the puncture extravascularly with a polyethylene glycol sealant, clip-based devices close the arteriotomy with a small metal clip, and dedicated large-bore devices use bioresorbable patches, plugs, and membranes. Suture-mediated devices are expected to retain their leading share throughout the forecast period, reinforced by the growth of large-bore procedures.

By Access Site

Dominant Subsegment: Femoral.

The femoral category is expected to dominate the market.

Dominant: Femoral ~ 85%

The femoral segment accounted for an 85% share of the vascular closure devices market in 2025. The femoral access site dominates the access structure because the femoral artery remains the primary access route for the majority of cardiovascular and endovascular interventions, including large-bore procedures such as transcatheter aortic valve replacement and endovascular aneurysm repair, owing to its large caliber and the ease of catheter insertion it affords. Critically, femoral access carries a higher risk of bleeding and access-site complications than radial access, and this elevated risk is precisely what drives the demand for vascular closure devices, since suture-mediated approximators, collagen plugs, and sealant systems enable the rapid hemostasis, lower complication rates, and faster recovery that femoral punctures require. The large-bore structural heart and endovascular procedures that are growing most rapidly are performed almost exclusively through femoral access, because the radial artery is too small to accommodate the large sheaths involved, which concentrates the highest-value closure demand in the femoral segment. Supporting evidence from a study of over 28,000 atrial fibrillation patients showed that closure devices significantly reduced vascular complications and bleeding at the femoral site, reinforcing their clinical value. Radial access constitutes the second and growing segment, favored for routine coronary procedures because of its markedly lower bleeding risk, though it is frequently managed with a compression band rather than a closure device. The femoral segment is expected to retain its dominant share throughout the forecast period, anchored by the growth of large-bore femoral procedures.

Vascular Closure Devices Market Region Analysis

Dominant Region: North America

Dominant: North America ~ 45% (Largest)

North America accounted for a 45% share of the global vascular closure devices market in 2025. The region leads the global market, driven by the high prevalence of cardiovascular disease, an aging population that drives interventional procedure volume, and a well-established healthcare infrastructure, reinforced by high healthcare expenditure, rapid adoption of advanced technologies, favorable reimbursement, and a growing shift toward outpatient procedures that closure devices facilitate. According to DelveInsight estimates, the United States had some 38.6 million people living with diabetes in 2024, a figure projected to rise to 43.5 million by 2050, and in 2023 some 14 million males and a substantial number of females in the United States were affected by atherosclerotic cardiovascular disease, and the rising prevalence of diabetes and cardiovascular disease significantly boosts demand for closure devices because these conditions necessitate diagnostic and interventional procedures such as angiography, angioplasty, transcatheter aortic valve replacement, and endovascular aneurysm repair. Diabetic patients in particular face higher cardiovascular risk, requiring frequent arterial access and making effective closure essential to minimize bleeding, enhance recovery, and improve safety. The increasing preference for minimally invasive procedures, which rely on limited puncture-based access rather than open incision, creates additional momentum, and the United States is the reference market for regulatory approval, hosting recent clearances of next-generation venous and small-bore arterial closure systems. High procedure volumes, chronic disease burden, and sustained innovation position North America as the leading market, and it is expected to retain its dominant position throughout the forecast period.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is projected to register the fastest compound annual growth rate in the vascular closure devices market through 2034. The region is emerging as a major growth driver, propelled by its large and growing patient population, the rising prevalence of diabetes and cardiovascular disease, and the increasing adoption of minimally invasive procedures. Rapid improvements in healthcare infrastructure, particularly in countries such as China, India, and Japan, are supporting higher volumes of catheter-based interventions including angioplasty and transcatheter aortic valve replacement, creating strong demand for reliable closure solutions. The expansion of catheterization laboratory capacity and interventional cardiology training is widening access to these procedures across the region. Greater awareness of advanced treatment options and rising investment by both global and regional players to introduce innovative closure devices, exemplified by the entry of emerging manufacturers securing their first regulatory approvals in Southeast Asian markets, are accelerating growth. Favorable government initiatives and improving reimbursement frameworks further boost adoption, and the coexistence of high-end international manufacturers and cost-competitive regional players broadens access across the price spectrum. China contributes the largest incremental volume, supported by a vast population, a rising cardiovascular burden, and a growing domestic device industry; Japan combines an aged population with advanced interventional practice and early adoption of bioresorbable closure; and India represents a substantial long-term opportunity as access broadens, tempered by price sensitivity. Regional growth is expected to exceed the global average across every segment, positioning Asia-Pacific as the fastest-growing market over the forecast period.

Regional Commentary

North America

North America leads on value, innovation, and regulatory precedence, holding a 45% share in 2025. The region combines a high cardiovascular and diabetes burden with advanced catheterization infrastructure, favorable reimbursement, high healthcare spending, and a strong shift toward outpatient procedures. DelveInsight estimates some 38.6 million people in the United States were living with diabetes in 2024, rising to 43.5 million by 2050. The United States is the reference market for new closure approvals, including next-generation venous and small-bore arterial systems. Near-term dynamics are shaped by the expansion of large-bore structural heart procedures, the shift to same-day discharge, bioresorbable closure, and tariff-driven supply reconfiguration.

Europe

Europe is a large and innovation-oriented market, driven by a rising cardiovascular disease burden, an aging population requiring more interventional procedures, and strong adoption of minimally invasive techniques such as angioplasty, transcatheter aortic valve replacement, and endovascular aneurysm repair. The region benefits from well-established healthcare infrastructure, growing investment in catheter-based intervention, and widespread physician preference for closure devices over manual compression, and it is frequently an early market for innovative large-bore and bioresorbable systems, exemplified by the CE Mark and expanded indication for fully bioresorbable sutureless large-bore closure. Supportive reimbursement across many European countries strengthens adoption, while the European Union Medical Device Regulation has raised the evidentiary burden for new approvals.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a large and growing patient population, rising diabetes and cardiovascular disease prevalence, and increasing adoption of minimally invasive procedures. Rapid infrastructure improvement in China, India, and Japan supports higher volumes of catheter-based intervention, and rising investment by global and regional players, improving reimbursement, and government initiatives accelerate growth. China contributes the largest incremental volume, Japan combines deep aging with early bioresorbable adoption, and India offers a substantial long-term opportunity tempered by price sensitivity. The coexistence of international and cost-competitive regional manufacturers broadens access, and growth exceeds the global average across every segment.

Rest of World

The Rest of the World comprises the Middle East, Africa, and South America. Access is highly stratified. The Gulf Cooperation Council states and the larger South American markets, particularly Brazil, have invested in catheterization and structural heart capacity and increasingly perform contemporary interventional procedures with closure, representing growing markets, while much of Africa lacks the catheterization infrastructure, trained interventional workforce, and financing required, so a large share of cardiovascular disease is never treated interventionally. Cost and reimbursement constraints limit closure device penetration in developing countries. Regional growth will be driven by investment in cardiac catheterization capacity, rising cardiovascular burden, government health initiatives, and lower-cost devices from regional and Asian manufacturers.

Vascular Closure Devices Market Competitive Landscape

The global vascular closure devices market is classified as Moderately Consolidated. A small group of large medical technology companies, including Abbott, Terumo, Cardinal Health through Cordis, and Teleflex, dominates through strong brand presence, broad closure portfolios, and global distribution networks, while smaller companies drive innovation with bioabsorbable and specialized large-bore and venous closure solutions, often leading to acquisition by the larger firms. Competition centers increasingly on large-bore closure for procedures such as transcatheter aortic valve replacement and endovascular aneurysm repair, where dedicated technologies are becoming critical, and strategic mergers, partnerships, and geographic expansion into high-growth regions intensify the contest. The competitive landscape is evaluated across the following dimensions:

  • Market concentration: Moderately consolidated, with a small group of large medical technology companies holding the majority of revenue through established closure franchises, alongside a growing tier of large-bore, bioresorbable, and venous closure specialists.
  • Leading players: Abbott leads with its market-share-leading Perclose suture-mediated franchise, Terumo holds an entrenched position with the collagen-plug Angio-Seal, Teleflex competes in large-bore with MANTA, Cardinal Health through Cordis offers the MYNX sealant, and Haemonetics has built a venous and large-bore franchise through the Vascade portfolio and the Vivasure acquisition.
  • Geographic reach: The leading participants maintain global commercial and clinical-education organizations built upon catheterization laboratory relationships, while regional manufacturers including Meril and Zylox-Tonbridge leverage cost advantages to serve price-sensitive and emerging markets.
  • Product portfolio strength: Competitive advantage rests on breadth across closure mechanisms and sheath sizes, since operators select devices by procedure, and a portfolio spanning small-bore suture, collagen, and sealant devices through dedicated large-bore systems is the decisive competitive asset.
  • Pipeline strength: Development is concentrated in dedicated large-bore closure for structural heart procedures, fully bioresorbable and sutureless systems, next-generation suture-mediated and sealant devices, and venous closure for electrophysiology and left atrial appendage procedures.
  • Strategic partnerships: Collaboration spans alliances between closure developers and structural heart programs and clinical trial partnerships, exemplified by partnerships between Haemonetics and Vivasure, Teleflex and InSeal Medical, and Abbott and Essential Medical.
  • M&A activity: Acquisition is a defining dynamic, exemplified by the Haemonetics acquisitions of Cardiva Medical and Vivasure Medical to build large-bore and venous closure, the Haemonetics acquisition of OpSens, and the Teleflex agreement to acquire the Biotronik vascular intervention business to complement MANTA.
  • Innovation focus: Innovation is shifting toward large-bore and fully bioresorbable closure, sutureless and faster-resorbing sealant technologies, venous and structural heart closure, and the integration of artificial intelligence into access-site planning and deployment guidance.
  • Regulatory standing: United States premarket approval and 510(k) clearance and European Union Medical Device Regulation certification are decisive competitive credentials, and the sequence of large-bore and venous closure approvals has become a principal axis of competition among the leaders.

Vascular Closure Devices Market Recent Developmental Activities

In January 2026, Haemonetics Corporation acquired Vivasure Medical for a reported USD 116 million upfront, expanding into large-bore structural heart and endovascular closure through the fully bioresorbable, sutureless PerQseal platform. Strategic significance: the acquisition gave a growing closure specialist a leading fully bioresorbable large-bore platform and a foothold in the fastest-growing segment of the market, consolidating large-bore closure among the larger players and intensifying competition for the structural heart opportunity.

Vascular Closure Devices Market Segmentation

Vascular Closure Devices Market Assessment by Closure Mechanism

  • Suture-Mediated Devices (Active Approximators)
  • Collagen-Plug Devices
  • Sealant and Gel-Based Devices
  • Clip-Based Devices
  • Dedicated Large-Bore Closure Devices (Patch, Plug, and Membrane)
  • Assisted Compression and Others

Vascular Closure Devices Market Assessment by Access Site

  • Femoral
  • Radial

Vascular Closure Devices Market Assessment by Sheath Size

  • Small-Bore (5-10F)
  • Large-Bore (12-25F)

Vascular Closure Devices Market Assessment by End-User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

Vascular Closure Devices Market Assessment by Geography

  • North America
  • United States Vascular Closure Devices Market Size in USD million (2023-2034)
  • Canada Vascular Closure Devices Market Size in USD million (2023-2034)
  • Mexico Vascular Closure Devices Market Size in USD million (2023-2034)
  • Europe
  • France Vascular Closure Devices Market Size in USD million (2023-2034)
  • Germany Vascular Closure Devices Market Size in USD million (2023-2034)
  • United Kingdom Vascular Closure Devices Market Size in USD million (2023-2034)
  • Italy Vascular Closure Devices Market Size in USD million (2023-2034)
  • Spain Vascular Closure Devices Market Size in USD million (2023-2034)
  • Rest of Europe Vascular Closure Devices Market Size in USD million (2023-2034)
  • Asia-Pacific
  • China Vascular Closure Devices Market Size in USD million (2023-2034)
  • Japan Vascular Closure Devices Market Size in USD million (2023-2034)
  • India Vascular Closure Devices Market Size in USD million (2023-2034)
  • Australia Vascular Closure Devices Market Size in USD million (2023-2034)
  • South Korea Vascular Closure Devices Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Vascular Closure Devices Market Size in USD million (2023-2034)
  • Rest of the World
  • Middle East Vascular Closure Devices Market Size in USD million (2023-2034)
  • Africa Vascular Closure Devices Market Size in USD million (2023-2034)
  • South America Vascular Closure Devices Market Size in USD million (2023-2034)

Key Takeaways from the Vascular Closure Devices Market Report Study

  • Market size analysis for the current vascular closure devices market size (2025), and market forecast for 9 years (2026 to 2034).
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
  • Key companies dominating the global vascular closure devices market.
  • Various opportunities available for competitors in the vascular closure devices market space.
  • What are the top-performing segments in 2025? How will these segments perform in 2034?
  • Which are the top-performing regions and countries in the current vascular closure devices market scenario?
  • Which are the regions and countries where companies should concentrate their opportunities for vascular closure devices market growth in the future?

Target audience who can benefit from this Vascular Closure Devices market report study

  • Herbal medicines product providers
  • Research organizations and consulting companies
  • Herbal medicines-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in vascular closure devices
  • Various end-users who want to know more about the vascular closure devices market and the latest technological developments in the vascular closure devices market.

Frequently Asked Questions:

Q1. At what rate is the vascular closure devices market expected to grow?

The global vascular closure devices market is projected to grow at a compound annual growth rate of 5.70% during the forecast period from 2026 to 2034.

Q2. What is the current and projected size of the vascular closure devices market?

The global vascular closure devices market was valued at USD 1.64 billion in 2025 and is projected to reach USD 2.70 billion by 2034.

Q3. Which region dominates the vascular closure devices market?

North America dominated the vascular closure devices market with a 45% share in 2025, driven by the high prevalence of cardiovascular disease and diabetes, an aging population, advanced catheterization infrastructure, favorable reimbursement, high healthcare spending, and a strong shift toward outpatient procedures, with DelveInsight estimating some 38.6 million people in the United States living with diabetes in 2024. Asia-Pacific is projected to record the fastest compound annual growth rate through 2034, driven by a large and growing patient population, rising diabetes and cardiovascular disease prevalence, and expanding catheterization capacity across China, India, and Japan.

Table of Contents

1. Introduction

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Market Overview at a Glance

2. Executive Summary of Vascular Closure Devices Market

  • 2.1. Key Highlights and Market Snapshot

3. Key Factors Impacting the Vascular Closure Devices Market

  • 3.1. Market Drivers
    • 3.1.1. Rising Prevalence of Cardiovascular Disease and Diabetes
    • 3.1.2. Growing Adoption of Minimally Invasive Procedures
    • 3.1.3. Expansion of Large-Bore Structural Heart Procedures
    • 3.1.4. Technological Advancement and Bioabsorbable Materials
  • 3.2. Market Restraints
    • 3.2.1. Risk of Complications Associated with Closure Devices
    • 3.2.2. Stringent Regulatory Standards
    • 3.2.3. Competition from Manual Compression and Radial Access
  • 3.3. Market Opportunities
    • 3.3.1. Fully Bioresorbable and Large-Bore Closure
    • 3.3.2. Venous Closure and Emerging Markets

4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments

5. Regulatory Analysis

  • 5.1. The United States
  • 5.2. Europe
  • 5.3. Japan
  • 5.4. China

6. Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Vascular Closure Devices Market Assessment

  • 7.1. By Closure Mechanism
    • 7.1.1. Suture-Mediated Devices (Active Approximators)
    • 7.1.2. Collagen-Plug Devices
    • 7.1.3. Sealant and Gel-Based Devices
    • 7.1.4. Clip-Based Devices
    • 7.1.5. Dedicated Large-Bore Closure Devices (Patch, Plug, and Membrane)
    • 7.1.6. Assisted Compression and Others
  • 7.2. By Access Site
    • 7.2.1. Femoral
    • 7.2.2. Radial
  • 7.3. By Sheath Size
    • 7.3.1. Small-Bore (5-10F)
    • 7.3.2. Large-Bore (12-25F)
  • 7.4. By End-User
    • 7.4.1. Hospitals and Clinics
    • 7.4.2. Ambulatory Surgical Centers
    • 7.4.3. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.1.2. Canada Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.1.3. Mexico Vascular Closure Devices Market Size in USD million (2023-2034)
    • 7.5.2. Europe
      • 7.5.2.1. France Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.2.2. Germany Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.2.3. United Kingdom Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.2.4. Italy Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.2.5. Spain Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.2.6. Rest of Europe Vascular Closure Devices Market Size in USD million (2023-2034)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.3.2. Japan Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.3.3. India Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.3.4. Australia Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.3.5. South Korea Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.3.6. Rest of Asia-Pacific Vascular Closure Devices Market Size in USD million (2023-2034)
    • 7.5.4. Rest of the World
      • 7.5.4.1. Middle East Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.4.2. Africa Vascular Closure Devices Market Size in USD million (2023-2034)
      • 7.5.4.3. South America Vascular Closure Devices Market Size in USD million (2023-2034)

8. Vascular Closure Devices Market Competitive Landscape

  • 8.1. Competitive Analysis
  • 8.2. Company Share Analysis (Premium Offering)

9. Vascular Closure Devices Market Startup Funding and Investment Trends

10. Company and Product Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Company Snapshot
    • 10.1.3. Financial Overview
    • 10.1.4. Product Listing
    • 10.1.5. Strategic Initiatives / Entropy
  • 10.2. Terumo Corporation
    • 10.2.1. Company Overview
    • 10.2.2. Company Snapshot
    • 10.2.3. Financial Overview
    • 10.2.4. Product Listing
    • 10.2.5. Strategic Initiatives / Entropy
  • 10.3. Teleflex Incorporated
    • 10.3.1. Company Overview
    • 10.3.2. Company Snapshot
    • 10.3.3. Financial Overview
    • 10.3.4. Product Listing
    • 10.3.5. Strategic Initiatives / Entropy
  • 10.4. Cardinal Health (Cordis)
    • 10.4.1. Company Overview
    • 10.4.2. Company Snapshot
    • 10.4.3. Financial Overview
    • 10.4.4. Product Listing
    • 10.4.5. Strategic Initiatives / Entropy
  • 10.5. Haemonetics Corporation
    • 10.5.1. Company Overview
    • 10.5.2. Company Snapshot
    • 10.5.3. Financial Overview
    • 10.5.4. Product Listing
    • 10.5.5. Strategic Initiatives / Entropy
  • 10.6. Medtronic plc
    • 10.6.1. Company Overview
    • 10.6.2. Company Snapshot
    • 10.6.3. Financial Overview
    • 10.6.4. Product Listing
    • 10.6.5. Strategic Initiatives / Entropy
  • 10.7. Merit Medical Systems Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Company Snapshot
    • 10.7.3. Financial Overview
    • 10.7.4. Product Listing
    • 10.7.5. Strategic Initiatives / Entropy
  • 10.8. Becton, Dickinson and Company (BD)
    • 10.8.1. Company Overview
    • 10.8.2. Company Snapshot
    • 10.8.3. Financial Overview
    • 10.8.4. Product Listing
    • 10.8.5. Strategic Initiatives / Entropy
  • 10.9. Vivasure Medical Ltd.
    • 10.9.1. Company Overview
    • 10.9.2. Company Snapshot
    • 10.9.3. Financial Overview
    • 10.9.4. Product Listing
    • 10.9.5. Strategic Initiatives / Entropy
  • 10.10. Vasorum Ltd.
    • 10.10.1. Company Overview
    • 10.10.2. Company Snapshot
    • 10.10.3. Financial Overview
    • 10.10.4. Product Listing
    • 10.10.5. Strategic Initiatives / Entropy

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer and Contact Us

List of Tables

  • Table 1: Global Vascular Closure Devices Market Size in USD million (2023-2034)
  • Table 2: Global Vascular Closure Devices Market Size by Closure Mechanism in USD million (2023-2034)
  • Table 3: Global Vascular Closure Devices Market Size by Access Site in USD million (2023-2034)
  • Table 4: Global Vascular Closure Devices Market Size by Sheath Size in USD million (2023-2034)
  • Table 5: Global Vascular Closure Devices Market Size by End-User in USD million (2023-2034)
  • Table 6: Vascular Closure Devices Market Size in North America in USD million (2023-2034)
  • Table 7: Vascular Closure Devices Market Size in the United States in USD million (2023-2034)
  • Table 8: Vascular Closure Devices Market Size in Canada in USD million (2023-2034)
  • Table 9: Vascular Closure Devices Market Size in Mexico in USD million (2023-2034)
  • Table 10: Vascular Closure Devices Market Size in Europe in USD million (2023-2034)
  • Table 11: Vascular Closure Devices Market Size in France in USD million (2023-2034)
  • Table 12: Vascular Closure Devices Market Size in Germany in USD million (2023-2034)
  • Table 13: Vascular Closure Devices Market Size in the United Kingdom in USD million (2023-2034)
  • Table 14: Vascular Closure Devices Market Size in Italy in USD million (2023-2034)
  • Table 15: Vascular Closure Devices Market Size in Spain in USD million (2023-2034)
  • Table 16: Vascular Closure Devices Market Size in the Rest of Europe in USD million (2023-2034)
  • Table 17: Vascular Closure Devices Market Size in Asia-Pacific in USD million (2023-2034)
  • Table 18: Vascular Closure Devices Market Size in China in USD million (2023-2034)
  • Table 19: Vascular Closure Devices Market Size in Japan in USD million (2023-2034)
  • Table 20: Vascular Closure Devices Market Size in India in USD million (2023-2034)
  • Table 21: Vascular Closure Devices Market Size in Australia in USD million (2023-2034)
  • Table 22: Vascular Closure Devices Market Size in South Korea in USD million (2023-2034)
  • Table 23: Vascular Closure Devices Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Table 24: Vascular Closure Devices Market Size in the Rest of the World in USD million (2023-2034)
  • Table 25: Vascular Closure Devices Market Size in the Middle East in USD million (2023-2034)
  • Table 26: Vascular Closure Devices Market Size in Africa in USD million (2023-2034)
  • Table 27: Vascular Closure Devices Market Size in South America in USD million (2023-2034)
  • Table 28: Vascular Closure Devices Market Competitive Landscape
  • Table 29: Vascular Closure Devices Market Startup Funding and Investment Trends

List of Figures

  • Figure 1: Vascular Closure Devices Market Drivers
  • Figure 2: Vascular Closure Devices Market Restraints
  • Figure 3: Vascular Closure Devices Market Opportunities
  • Figure 4: Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
  • Figure 5: Regulatory Analysis of the Vascular Closure Devices Market (the United States)
  • Figure 6: Regulatory Analysis of the Vascular Closure Devices Market (Europe)
  • Figure 7: Regulatory Analysis of the Vascular Closure Devices Market (Japan)
  • Figure 8: Regulatory Analysis of the Vascular Closure Devices Market (China)
  • Figure 9: Porter's Five Forces Analysis of the Vascular Closure Devices Market
  • Figure 10: Competitive Analysis of the Vascular Closure Devices Market
  • Figure 11: Global Vascular Closure Devices Market Size in USD million (2023-2034)
  • Figure 12: Global Vascular Closure Devices Market Size by Closure Mechanism in USD million (2023-2034)
  • Figure 13: Global Vascular Closure Devices Market Size by Access Site in USD million (2023-2034)
  • Figure 14: Global Vascular Closure Devices Market Size by Sheath Size in USD million (2023-2034)
  • Figure 15: Global Vascular Closure Devices Market Size by End-User in USD million (2023-2034)
  • Figure 16: Vascular Closure Devices Market Size in North America in USD million (2023-2034)
  • Figure 17: Vascular Closure Devices Market Size in the United States in USD million (2023-2034)
  • Figure 18: Vascular Closure Devices Market Size in Canada in USD million (2023-2034)
  • Figure 19: Vascular Closure Devices Market Size in Mexico in USD million (2023-2034)
  • Figure 20: Vascular Closure Devices Market Size in Europe in USD million (2023-2034)
  • Figure 21: Vascular Closure Devices Market Size in France in USD million (2023-2034)
  • Figure 22: Vascular Closure Devices Market Size in Germany in USD million (2023-2034)
  • Figure 23: Vascular Closure Devices Market Size in the United Kingdom in USD million (2023-2034)
  • Figure 24: Vascular Closure Devices Market Size in Italy in USD million (2023-2034)
  • Figure 25: Vascular Closure Devices Market Size in Spain in USD million (2023-2034)
  • Figure 26: Vascular Closure Devices Market Size in the Rest of Europe in USD million (2023-2034)
  • Figure 27: Vascular Closure Devices Market Size in Asia-Pacific in USD million (2023-2034)
  • Figure 28: Vascular Closure Devices Market Size in China in USD million (2023-2034)
  • Figure 29: Vascular Closure Devices Market Size in Japan in USD million (2023-2034)
  • Figure 30: Vascular Closure Devices Market Size in India in USD million (2023-2034)
  • Figure 31: Vascular Closure Devices Market Size in Australia in USD million (2023-2034)
  • Figure 32: Vascular Closure Devices Market Size in South Korea in USD million (2023-2034)
  • Figure 33: Vascular Closure Devices Market Size in the Rest of Asia-Pacific in USD million (2023-2034)
  • Figure 34: Vascular Closure Devices Market Size in the Rest of the World in USD million (2023-2034)
  • Figure 35: Vascular Closure Devices Market Size in the Middle East in USD million (2023-2034)
  • Figure 36: Vascular Closure Devices Market Size in Africa in USD million (2023-2034)
  • Figure 37: Vascular Closure Devices Market Size in South America in USD million (2023-2034)
  • Figure 38: Vascular Closure Devices Market Competitive Landscape
  • Figure 39: Vascular Closure Devices Market Startup Funding and Investment Trends